Nuclear medical inpatient treatment in Germany

2010 ◽  
Vol 49 (02) ◽  
pp. 49-57 ◽  
Author(s):  
M. Dietlein ◽  
C. Reiners ◽  
R. Lorenz
Keyword(s):  
Nuclear Medicine ◽  
Thyroid Cancer ◽  
Inpatient Treatment ◽  
Radioiodine Therapy ◽  
Main Diagnosis ◽  
Medical Inpatient ◽  
Iodine Prophylaxis ◽  
Iodine Supply ◽  
Quality Report ◽  
Quality Reports

SummaryAll public licensed hospitals of Germany are obligated since 2004 to establish and to publish a structured biennial quality report. The aim of this study was to analyse the quality reports from 2008 of clinics with nuclear-medicine therapy ward and to investigate developments for the inpatient nuclear-medicine therapy by comparing the results with the quality reports of the years 2004 and 2006. Methods: All available structured quality reports of clinics with a nuclear-medicine therapy ward of the years 2004, 2006 and 2008 were evaluated. Results: The total number of inpatient treatment cases in 2008 amounted to 54 190 (2006: 54 884; 2004: 57 366). This corresponds to a decrease of 5.5% in comparison to 2004. The number of the therapy wards decreased at the same time to currently 117 (2006: 120; 2004: 124). Remarkable changes were found in the spectrum of the main diagnosis. Thus, the most frequent diagnosis with the ICD-code E05 (hyperthyroidism) decreased continuously from 37 747 treatments in 2004 and 34 764 in 2006 to 31 756 in the year 2008. In contrast, the ICD-diagnoses for thyroid cancer (C73, Z08) with 14 761 cases in 2008 increased with time (2006: 13 426; 2004: 12 581). Conclusions: In analogy to the observations from Europe after introduction of an iodine prophylaxis the improved iodine supply in Germany has led to a decline of the radioiodine therapy due to hyperthyroidism.

Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)

2004 ◽  
Vol 43 (04) ◽  
pp. 115-120 ◽  
Author(s):  
J. Dressler ◽  
J. Farahati ◽  
F. Grünwald ◽  
B. Leisner ◽  
E. Moser ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Tnm Classification ◽  
Whole Body ◽  
Procedure Guidelines ◽  
Special Cases ◽  
Deutsche Gesellschaft Für Chirurgie ◽  
Thyroglobulin Concentration

SummaryThe procedure guidelines for radioiodine therapy (RIT) of differentiated thyroid cancer (version 2) are the counterpart to the procedure guidelines for 131I whole-body scintigraphy (version 2) and specify the interdisciplinary guidelines for thyroid cancer of the Deutsche Krebs-gesellschaft and the Deutsche Gesellschaft für Chirurgie concerning the nuclear medicine part. Compared with version 1 facultative options for RIT can be chosen in special cases: ablative RIT for papillary microcarcinoma ≤1 cm, ablative RIT for mixed forms of anaplastic and differentiated thyroid cancer, and RIT in patients with a measurable or increasing thyroglobulin concentration but without detectable metastases by imaging. The description of the pretherapeutic dosimetry now includes the isotopes 123I and 124I as well as a broader range of the activity of 131I. Activities of 2-5 GBq 131I are recommended for the first ablative RIT. If high accumulative activities of 131I are expected, men who have not yet finished their family planning should be advised to the option of sperm cryoconservation. An interdisciplinary consensus is necessary whether the new TNM-classification (UICC, 6th edition, 2002) will lead to modified recommendations for surgical or nuclear medicine therapy, especially for the surgical completeness and for the ablative RIT of pT1 papillary cancer.

scholarly journals Theranostics in Nuclear Medicine Practice

2017 ◽  
Author(s):  
Anna Yordanova ◽  
Elisabeth Eppard ◽  
Stefan Kürpig ◽  
Stefan Schönberger ◽  
Maria Gonzalez-Carmona ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Thyroid Cancer ◽  
Personalized Medicine ◽  
Targeted Therapies ◽  
Radioiodine Therapy ◽  
Diagnostic Techniques ◽  
Molecular Targeting ◽  
Theranostic Agents ◽  
Nuclear Medicine Practice ◽  
Diagnostics And Therapy

The importance of personalized medicine is growing, since there is an urged need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic approach is an established tool for a specific molecular targeting in means of diagnostics and therapy. The visualisation of potential targets can help to predict if a patient would benefit from a particular treatment or not. Thanks to the quick development of radiopharmaceuticals and diagnostic techniques, the use of theranostic agents is constantly rising. In this article important milestones of nuclear therapies and diagnostics in the context of theranostics are highlighted. It begins with the well-known radioiodine therapy in patients with thyroid cancer and then guides through different approaches for the treatment of advanced cancer with targeted therapies. The aim of this review is to provide a summary of background knowledge, current applications and advantages of targeted therapies and imaging in nuclear medicine practice.

Nuklearmedizin in Deutschland

1989 ◽  
Vol 28 (01) ◽  
pp. 1-10
Author(s):  
C. Winkler
Keyword(s):  
Nuclear Medicine ◽  
Thyroid Cancer ◽  
Clinical Practice ◽  
Radioiodine Therapy ◽  
State Of The Art ◽  
The State ◽  
Stepping Stones ◽  
Scintigraphic Imaging ◽  
Basic Principles

The development of nuclear medicine in Germany from early approaches with 32P and 1311 to the first radioiodine therapy of thyroid cancer up to the clarification of basic principles for current thyroid diagnostics and for functional scintigraphic imaging are presented. Selected references are used in portraying scientific stepping stones of our speciality as well as its establishment in clinical practice during the first two decades. Researchers, places, and facts are specified and interpreted in their relation to the state-of-the-art of nuclear medicine.

Predictive factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer

2020 ◽  
Vol 64 (1) ◽  
Author(s):  
Ewelina Szczepanek-Parulska ◽  
Magdalena Wojewoda-Korbelak ◽  
Martyna Borowczyk ◽  
Malgorzata Kaluzna ◽  
Barbara Brominska ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Predictive Factors ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Incomplete Response

scholarly journals Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Charles Timäus ◽  
Miriam Meiser ◽  
Borwin Bandelow ◽  
Kirsten R. Engel ◽  
Anne M. Paschke ◽  
...  
Keyword(s):  
Borderline Personality Disorder ◽  
Personality Disorder ◽  
Psychotropic Drug ◽  
Inpatient Treatment ◽  
Medical Center ◽  
Borderline Personality ◽  
Mood Stabilizers ◽  
Main Diagnosis ◽  
Tetracyclic Antidepressants ◽  
Prescription Rates

Abstract Background The purpose of this study was to assess the pharmacological treatment strategies of inpatients with borderline personality disorder between 2008 and 2012. Additionally, we compared pharmacotherapy during this period to a previous one (1996 to 2004). Methods Charts of 87 patients with the main diagnosis of borderline personality disorder receiving inpatient treatment in the University Medical Center of Goettingen, Germany, between 2008 and 2012 were evaluated retrospectively. For each inpatient treatment, psychotropic drug therapy including admission and discharge medication was documented. We compared the prescription rates of the interval 2008–2012 with the interval 1996–2004. Results 94% of all inpatients of the interval 2008–2012 were treated with at least one psychotropic drug at time of discharge. All classes of psychotropic drugs were applied. We found high prescription rates of naltrexone (35.6%), quetiapine (19.5%), mirtazapine (18.4%), sertraline (12.6%), and escitalopram (11.5%). Compared to 1996–2004, rates of low-potency antipsychotics, tri−/tetracyclic antidepressants and mood stabilizers significantly decreased while usage of naltrexone significantly increased. Conclusions In inpatient settings, pharmacotherapy is still highly prevalent in the management of BPD. Prescription strategies changed between 1996 and 2012. Quetiapine was preferred, older antidepressants and low-potency antipsychotics were avoided. Opioid antagonists are increasingly used and should be considered for further investigation.

scholarly journals Radioiodine therapy reduces the frequency of circulating tumour cells in patients with differentiated thyroid cancer

2021 ◽  
Author(s):  
Mathias Schmidt ◽  
Christina Antke ◽  
Katalin Mattes‐György ◽  
Hubertus Hautzel ◽  
Stephanie Allelein ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Tumour Cells ◽  
Circulating Tumour Cells
Sign in / Sign up

Export Citation Format

Share Document